DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Information source: Grifols Therapeutics Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alpha 1-Antitrypsin Deficiency

Intervention: Alpha1-Proteinase Inhibitor (Human) (Drug); Albumin (Human) 20%, United States Pharmacopeia (USP) (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Grifols Therapeutics Inc.

Official(s) and/or principal investigator(s):
Asger Dirksen, MD PHD, Principal Investigator, Affiliation: University of Copenhagen


The goal of this trial was to explore the utility of evaluating emphysema progression through CT scans measuring lung density during a 2 year period of weekly infusions of either placebo or human alpha-1-antitrypsin (AAT; Prolastin®). Exacerbation data recorded in patient diaries were also collected. All efficacy data were analyzed for potential use in evaluating Prolastin efficacy in this and other clinical trials.

Clinical Details

Official title: Multi-center, Randomized Trial With I.V. Prolastin® to Evaluate Frequency of Exacerbations and Progression of Emphysema by Means of Multi-slice CT Scans in Patients With Congenital Alpha-1-antitrypsin Deficiency.

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The Progression Rate of Emphysema Determined by Change in 15th Percentile of Lung Density Measured by Annual CT Scan of the Whole Lung

Secondary outcome:

Change in Lung Density at Each Visit as Measured by Computed Tomography

The Frequency of Exacerbations as Determined by Patient Diary.

The Deterioration of the Lung Function Will be Assessed by Measurement of the Change in Forced Expiratory Volume at One Second (FEV1) and Transfer Factor of Carbon Monoxide (KCO)

Duration and Severity of the Exacerbations


Quality of Life With a Disease Specific Instrument, the St. George's Respiratory Questionnaire

Detailed description: This is a one to one randomized, placebo-controlled, clinical, exploratory study with the aim of collecting information on possible clinical endpoints i. e., the progression of emphysema by lung density measurements with CT scan and frequency of exacerbations that could be used for a subsequent placebo controlled clinical trial. Progression of disease will be investigated in 80 patients with alpha-1-antitrypsin deficiency, who will be treated with human alpha-1-antitrypsin (AAT; Prolastin®) or placebo weekly for two years to analyze the effect of treatment on lung density and exacerbations. Targeted augmentation therapy with weekly infusions of Prolastin® will be a dose of 60 mg/kg body weight (range of 51. 72 to 71. 43 mg per kg body weight). Therefore, this study focuses on several questions:

- Is the 15th percentile point calculated by analysis of CT lung histograms a useful

endpoint for clinical trials in AAT deficiency?

- Is quantitation of exacerbations in AAT-deficient patients a useful endpoint for

clinical trials in AAT deficiency?

- Are there significant differences between the treatments in favor of Prolastin®?


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patient with pulmonary emphysema due to severe congenital AAT deficiency of phenotype

protease inhibitor Z (PiZ) or other rare genotypes (not MS, MZ or SZ) and AAT serum level < 11 microns (µM) or < 80 mg/dL (status to be confirmed by phenotyping and genotyping)

- Inspiratory capacity (VC - ERV) > 1. 2 L and forced expiratory volume at one second

(FEV1) < 80% of predicted value post bronchodilator

- FEV1/VC < 70% of predicted value post-bronchodilator or transfer factor of carbon

monoxide (KCO) < 80% of predicted value post-bronchodilator

- History of at least one exacerbation in the past 2 years

- Written informed consent

Exclusion Criteria:

- FEV1 < 25% of predicted value post-bronchodilator

- Augmentation therapy for more than one month with plasma-derived human alpha

1-antitrypsin (AAT) within the last 2 years

- History of lung transplant

- Any lung surgery within the past 2 years

- On any thoracic surgery waiting list

- Diagnosis of liver cirrhosis

- Severe concomitant disease

- Active pulmonary infection/exacerbations within the last month

- Active smoking during the last 6 months or plasma positive for cotinine

- Body weight < 42 kg or > 92 kg

- Pregnancy or lactation

- Women of child-bearing potential without adequate contraception

Locations and Contacts

Gentofte Hospital Department of Respiratory Medicine, Hellerup 2900, Denmark

Department of Pulmonary Medicine, Malmö University Hospital, Malmö, Sweden

Queen Elizabeth Hospital, Birmingham, England B15 2TH, United Kingdom

Additional Information

FDA Approved Product Labeling Information - Prolastin®

FDA Enforcement, Report Index (Class I, Class II Recall, Market Alerts and Medical Product Safety Alerts)

FDA Approved Product Labeling Information - Plasbumin®-20 (Low Aluminum)

Starting date: December 2003
Last updated: August 5, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017